Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Given Consensus Rating of "Hold" by Analysts

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) has received a consensus recommendation of "Hold" from the five ratings firms that are presently covering the stock, MarketBeat Ratings reports. Four equities research analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $8.00.

A number of equities research analysts have recently weighed in on VRCA shares. Needham & Company LLC reaffirmed a "hold" rating on shares of Verrica Pharmaceuticals in a research note on Wednesday, May 14th. Wall Street Zen raised Verrica Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright reaffirmed a "neutral" rating on shares of Verrica Pharmaceuticals in a research report on Tuesday, April 8th.

Verrica Pharmaceuticals Price Performance

Verrica Pharmaceuticals stock traded down $0.06 during trading on Monday, reaching $0.58. 262,581 shares of the company were exchanged, compared to its average volume of 588,909. Verrica Pharmaceuticals has a 52-week low of $0.38 and a 52-week high of $8.98. The company has a market capitalization of $53.53 million, a P/E ratio of -0.48 and a beta of 1.75. The stock's 50 day simple moving average is $0.54 and its two-hundred day simple moving average is $0.63.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.10) EPS for the quarter, beating analysts' consensus estimates of ($0.14) by $0.04. The business had revenue of $3.44 million during the quarter, compared to analysts' expectations of $2.53 million. As a group, equities analysts forecast that Verrica Pharmaceuticals will post -1.46 earnings per share for the current year.

Institutional Trading of Verrica Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. AQR Capital Management LLC lifted its position in Verrica Pharmaceuticals by 306.7% during the 1st quarter. AQR Capital Management LLC now owns 58,711 shares of the company's stock worth $26,000 after acquiring an additional 44,275 shares during the period. Invesco Ltd. purchased a new position in Verrica Pharmaceuticals in the 4th quarter valued at approximately $32,000. Charles Schwab Investment Management Inc. increased its stake in Verrica Pharmaceuticals by 127.9% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 99,505 shares of the company's stock valued at $44,000 after purchasing an additional 55,852 shares in the last quarter. Kovitz Investment Group Partners LLC purchased a new position in Verrica Pharmaceuticals in the 1st quarter valued at approximately $45,000. Finally, Goldman Sachs Group Inc. grew its holdings in Verrica Pharmaceuticals by 23.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 139,055 shares of the company's stock valued at $61,000 after buying an additional 26,308 shares during the last quarter. 42.45% of the stock is owned by institutional investors and hedge funds.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.